167 related articles for article (PubMed ID: 22431073)
21. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.
Linthorst GE; Hollak CE; Korevaar JC; Van Manen JG; Aerts JM; Boeschoten EW
Nephrol Dial Transplant; 2003 Aug; 18(8):1581-4. PubMed ID: 12897098
[TBL] [Abstract][Full Text] [Related]
22. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.
Vujasinovic M; Tepes B; Vujkovac B; Cokan Vujkovac A; Tretjak M; Korat V
Wien Klin Wochenschr; 2015 Dec; 127(23-24):931-4. PubMed ID: 25835592
[TBL] [Abstract][Full Text] [Related]
23. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.
Lin CJ; Chien YH; Lai TS; Shih HM; Chen YC; Pan CF; Chen HH; Hwu WL; Wu CJ
Kidney Blood Press Res; 2018; 43(5):1636-1645. PubMed ID: 30380558
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.
Hoffmann B; Schwarz M; Mehta A; Keshav S;
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1447-53. PubMed ID: 17919989
[TBL] [Abstract][Full Text] [Related]
25. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
26. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
27. [Psychiatric and neuropsychological signs and symptoms in patients with fabry disease: literature review].
Müller MJ; Müller KM; Dascalescu A; Whybra C; Baron K; Scheurich A; Mann K; Beck M; Schmidt LG; Fellgiebel A
Fortschr Neurol Psychiatr; 2005 Nov; 73(11):687-93. PubMed ID: 16283613
[TBL] [Abstract][Full Text] [Related]
28. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
29. Quality of life of patients with Fabry disease.
Gold KF; Pastores GM; Botteman MF; Yeh JM; Sweeney S; Aliski W; Pashos CL
Qual Life Res; 2002 Jun; 11(4):317-27. PubMed ID: 12086117
[TBL] [Abstract][Full Text] [Related]
30. Screening of family members of chronic kidney disease patients with Fabry disease mutations: a very important and underrated task.
Sodré LSS; Huaira RMNH; Colugnati FAB; Carminatti M; Braga LSS; Coutinho MP; Fernandes NMDS
J Bras Nefrol; 2021; 43(1):28-33. PubMed ID: 32930322
[TBL] [Abstract][Full Text] [Related]
31. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary approach to Fabry disease: from the eye of a neurologist.
İnan R; Meşe M; Bicik Z
Acta Neurol Belg; 2020 Dec; 120(6):1333-1339. PubMed ID: 30968323
[TBL] [Abstract][Full Text] [Related]
33. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
34. Frequency of Fabry disease in male and female haemodialysis patients in Spain.
Gaspar P; Herrera J; Rodrigues D; Cerezo S; Delgado R; Andrade CF; Forascepi R; Macias J; del Pino MD; Prados MD; de Alegria PR; Torres G; Vidau P; Sá-Miranda MC
BMC Med Genet; 2010 Feb; 11():19. PubMed ID: 20122163
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Caputo F; Lungaro L; Galdi A; Zoli E; Giancola F; Caio G; De Giorgio R; Zoli G
Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33807115
[TBL] [Abstract][Full Text] [Related]
36. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic
Doheny D; Srinivasan R; Pagant S; Chen B; Yasuda M; Desnick RJ
J Med Genet; 2018 Apr; 55(4):261-268. PubMed ID: 29330335
[TBL] [Abstract][Full Text] [Related]
37. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy.
Barba-Romero MÁ; Serena J; Puig JM; Valverde C V; Climent V; Herrero JA; Huertas R; Torra R
Med Clin (Barc); 2019 Jul; 153(2):47-55. PubMed ID: 30658922
[TBL] [Abstract][Full Text] [Related]
38. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.
Dobrovolny R; Dvorakova L; Ledvinova J; Magage S; Bultas J; Lubanda JC; Elleder M; Karetova D; Pavlikova M; Hrebicek M
J Mol Med (Berl); 2005 Aug; 83(8):647-54. PubMed ID: 15806320
[TBL] [Abstract][Full Text] [Related]
39. Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life.
Bouwman MG; Maurice-Stam H; Linthorst GE; Hollak CE; Wijburg FA; Grootenhuis MA
Mol Genet Metab; 2011 Nov; 104(3):308-13. PubMed ID: 21802328
[TBL] [Abstract][Full Text] [Related]
40. A survey of the pain experienced by males and females with Fabry disease.
Gibas AL; Klatt R; Johnson J; Clarke JT; Katz J
Pain Res Manag; 2006; 11(3):185-92. PubMed ID: 16960635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
